GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis
GENEVA--(BUSINESS WIRE)--GeNeuro SA, a pioneer of new therapies for neurology disorders, announced today positive results from a one-year, open-label extension of a Phase IIa study. GeNeuro tested its monoclonal antibody GNbAC1 in 10 multiple sclerosis (MS) patients, nine of which had primary or secondary progressive disease. GNbAC1 targets the MSRV-Env protein expressed by genes of endogenous retroviral origin, which GeNeuro believe plays a critical role in the pathogenesis of MS.
Help employers find you! Check out all the jobs and post your resume.